In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

GLP-1 receptor agonists linked to lower medication use and reduced headaches, visual disturbances or blindness, and papilledema.

Another study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

The Extended Lifespan of GLP-1 Receptor Agonist Drugs from the Discovery of Pleiotropic Effects Glucagon-like peptide-1 (GLP-1) was first discovered in the 1980s as a regulator of glucose levels.

Results showed that GLP-1 receptor agonist users (n = 162,346) were 1.36 times (95% CI, 1.1-1.69) or 36% more likely to develop acne 90 days after starting the medication than nonusers (n = 162,346).